
BIORQ
Healthcare · Biotechnology · $452 market cap
$0.00010.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2024
EPS trend, 90 days to now
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2024 | After the close | -3.85 | -5.04 | -30.9% |
| Aug 12, 2024 | After the close | -4.50 | -0.40 | +91.1% |
| May 15, 2024 | After the close | -4.50 | -1.40 | +68.9% |
| Mar 27, 2024 | Time not confirmed | -5.95 | -6.20 | -4.2% |
| Nov 13, 2023 | After the close | -9.25 | -48.90 | -428.6% |
| Aug 14, 2023 | After the close | -16.00 | -14.70 | +8.1% |
| May 15, 2023 | After the close | -17.50 | -15.90 | +9.1% |
| Nov 14, 2022 | After the close | -18.75 | -7.50 | +60.0% |
| Aug 15, 2022 | After the close | -30.00 | -7.50 | +75.0% |
| May 10, 2022 | After the close | -31.25 | -20.00 | +36.0% |
| Mar 28, 2022 | Time not confirmed | -0.16 | -0.56 | -250.0% |
| Nov 10, 2021 | After the close | -165.00 | -87.52 | +47.0% |
| Aug 12, 2021 | After the close | -203.75 |
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of…
| -141.74 |
| +30.4% |
| May 13, 2021 | After the close | -200.00 | -151.82 | +24.1% |
| Mar 18, 2021 | Time not confirmed | -0.82 | -1.53 | -86.1% |
| Nov 9, 2020 | After the close | -180.00 | -252.50 | -40.3% |
| Aug 13, 2020 | After the close | -202.50 | -265.25 | -31.0% |
| May 27, 2020 | Time not confirmed | — | -5.07 | — |